Re­treat­ing Ar­row­head ax­es CSO in RNAi rout; Im­pel rais­es $36M for plat­form tech

Now that Ar­row­head $AR­WR has de­cid­ed to chop out every­thing it has in the clin­ic, along with about a third of its staff, the biotech is giv­ing its CSO the boot as well. In an 8-K filed with the SEC, Ar­row­head said it had no­ti­fied David Lewis that his job ter­mi­nates on De­cem­ber 13. The re­treat at Ar­row­head has helped cast a pall over the RNAi field. A few weeks ago the biotech was forced to put its lead pro­gram on hold, and then fol­lowed up this week with the news that it is aban­don­ing three clin­i­cal-stage pro­grams. The news trig­gered a melt­down in its share price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.